Name: Aspirin
Brand: Selleck Chemicals
SKU: S3017
Rating: 5 (28 reviews)

바로가기

품질 관리

배치: 순도: 99.99%

99.99

관련 타겟	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
기타 COX 억제제	NS-398 (NS398) Paeoniflorin (NSC 178886) Lumiracoxib Xanthohumol Bufexamac Nimesulide Ginsenoside Rd Pranoprofen Phenacetin Tolfenamic Acid

세포 배양, 처리 및 작업 농도

세포주	분석 유형	농도	배양 시간	활성 설명	PMID
AGS	Function assay	15 to 60 umol/L after	12 hrs	Inhibition of Escherichia coli-stimulated IL-8 production in human AGS cells at 15 to 60 umol/L after 12 hrs by ELISA	20153183
microglia cells	Antineuroinflammatory assay		15 mins	Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge, IC50=3.12μM	22153874
HCT116	Function assay	1 mM	6 hrs	Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay	22154834
SKBR3	Growth inhibition assay	300 uM	48 hrs	Growth inhibition of human SKBR3 cells at 300 uM after 48 hrs by alamar blue assay	22494617
PANC1	Growth inhibition assay	300 uM	48 hrs	Growth inhibition of human PANC1 cells at 300 uM after 48 hrs by alamar blue assay	22494617
PC3	Growth inhibition assay	300 uM	48 hrs	Growth inhibition of human PC3 cells at 300 uM after 48 hrs by alamar blue assay	22494617
MDA-MB-231	Function assay	100 uM	30 mins	Irreversible inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay	23651359
THP1	Function assay	100 uM	30 mins	Irreversible inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay	23651359
HCT116	Cytotoxicity assay		48 hrs	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs MTT assay	26750401
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-6 in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of TNF-alpha in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by E	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring reduction in MDA levels at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring increase in SOD activity at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring increase in catalase activity at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of TNF-alpha in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-1beta in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as reduction in MDA levels at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring increase in SOD activity at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by spec	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-6 in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-1beta in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by EL	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced cytotoxicity in rat H9c2 cells assessed as increase in cell viability at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by MTT assay	27575471
RAW264.7	Antiinflammatory assay			Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method, IC50=43.2μM	28561586
stem cells	Function assay	100 uM	5 days	Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in adiponectin production at 100 uM measured on day 5 in presence of IDX by ELISA	29398443
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
peritoneal cells	Function assay		5 hrs	Inhibition of LPS-induced PGE2 production in C57BL6 mouse peritoneal cells measured at 5 hrs time interval by ELISA, IC50=4.08μM	30006172
HCT8	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay, IC50=15.6μM	30037494
RPMI8226	Cell cycle assay	1.7 uM	48 hrs	Cell cycle arrest in human RPMI8226 cells assessed as accumulation at G0/G1 phase at 1.7 uM in presence of bortezomib after 48 hrs by propidium iodide/RNase staining based flow cytometric method relative to bortezomib	30590258
RPMI8226	Cell cycle assay	1.7 uM	48 hrs	Cell cycle arrest in human RPMI8226 cells assessed as accumulation at S phase at 1.7 uM in presence of bortezomib after 48 hrs by propidium iodide/RNase staining based flow cytometric method relative to bortezomib	30590258
RPMI8226	Cell cycle assay	1.7 uM	48 hrs	Cell cycle arrest in human RPMI8226 cells assessed as reduction in accumulation at G2/M phase at 1.7 uM in presence of bortezomib after 48 hrs by propidium iodide/RNase staining based flow cytometric method relative to bortezomib	30590258
HaCaT	Antipyretic assay	100 uM	2 hrs	Antipyretic activity in human HaCaT cells assessed as inhibition of TNFalpha-induced PGE2 production at 100 uM pre-incubated for 2 hrs before TNFalpha stimulation for 24 hrs by ELISA	31393125
OVCAR5	Function assay	300 uM to 1 mM	72 hrs	Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor FK866-induced cytotoxicity by measuring reduction in cell viability at 300 uM to 1 mM incubated for 72 hrs by SRB assay	ChEMBL
CCRF-CEM	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human CCRF-CEM cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further	ChEMBL
Jurkat	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human Jurkat cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further i	ChEMBL
ML2	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human ML2 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incu	ChEMBL
NOMO	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human NOMO cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further inc	ChEMBL
NB4	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human NB4 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incu	ChEMBL
NAMALWA	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human NAMALWA cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further	ChEMBL
Daudi	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human Daudi cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further in	ChEMBL
Raji	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human Raji cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further inc	ChEMBL
ARH77	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human ARH77 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further in	ChEMBL
RPMI8226	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human RPMI8226 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further	ChEMBL
U266	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human U266 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further inc	ChEMBL
NAMALWA	Function assay	35 mg/kg	45 days	Potentiation of NAMPT inhibitor 10 mg/kg, ip bid FK866-induced antitumor activity in human NAMALWA cells xenografted in SCID mouse assessed as increase in mouse survival at 35 mg/kg, ip bid up to 45 days	ChEMBL
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량	180.16	화학식	C₉H₈O₄	보관 (수령일로부터)	3년-20°C분말
CAS 번호	50-78-2	SDF 다운로드		원액 보관	1년-80°C용매에 보관 1개월-20°C용매에 보관
동의어	NSC 27223, Acetylsalicylic acid, ASA			Smiles	CC(=O)OC1=CC=CC=C1C(=O)O

용해도

In vitro
배치:

DMSO : 36 mg/mL (199.82 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 36 mg/mL

Water : Insoluble

DMSO : 36 mg/mL (199.82 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 36 mg/mL

Water : Insoluble

몰농도 계산기

질량	농도	부피	분자량
=	×	×

희석 계산기 분자량 계산기

In vivo 배치:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

투여량: mg/kg 동물 평균 체중: g 동물당 투여량:μL 동물 수:

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH₂O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

Targets/IC₅₀/Ki	COX2 COX1
시험관 내(In vitro)	Aspirin은 NF-kappa B의 활성화를 억제하여 NF-kappa B 억제제인 I kappa B의 분해를 방지하며, 따라서 NF-kappa B는 세포질에 유지됩니다. 이 화합물은 또한 형질감염된 T 세포에서 Ig kappa 증강제 및 인간 면역결핍 바이러스 (HIV) 장기말단 반복 (LTR)으로부터의 NF-kappa B 의존성 전사를 억제합니다. Aspirin과 살리실산염의 작용은 부분적으로 IKK-베타의 특이적 억제를 통해 매개되며, 이는 염증 반응의 병인에 관련된 유전자의 NF-kappaB에 의한 활성화를 방지합니다. 이 화학물질은 쥐의 일차 신경 세포 배양 및 해마 절편에서 흥분성 아미노산 글루타메이트에 의해 유발되는 신경독성에 대해 보호 효과를 가집니다. 이는 인간 제대정맥 내피세포 (HUVEC)와 호중구 [다형핵 백혈구 (PMN)]의 동시 배양 중 이전에 알려지지 않은 종류의 에이코사노이드의 경세포 생합성을 유발합니다. 이 물질은 아세틸화된 PGHS-2와 5-리포산화효소 상호작용에 의해 형성되는 독특한 종류의 에이코사노이드를 유발합니다. 이 치료는 종양괴사인자 (TNF)-알파로 처리된 3T3-L1 및 Hep G2 세포에서 Ser307의 IRS-1 인산화뿐만 아니라 JNK, c-Jun 인산화 및 IkappaBalpha 분해를 억제합니다. 이 치료는 TNF-알파에 대한 반응으로 Akt 및 라파마이신 포유류 표적 (그러나 세포외 조절 키나제 또는 PKCzeta는 아님)의 인산화를 억제합니다. 이는 TNF-알파로 전처리된 3T3-L1 지방세포에서 인슐린 유도 포도당 흡수를 회복시킵니다.
참조	[1] https://pubmed.ncbi.nlm.nih.gov/8052854/ [2] https://pubmed.ncbi.nlm.nih.gov/9817203/ [3] https://pubmed.ncbi.nlm.nih.gov/8910280/ [4] https://pubmed.ncbi.nlm.nih.gov/7568157/ [5] https://pubmed.ncbi.nlm.nih.gov/12714600/

적용 분야

방법	바이오마커	이미지	PMID
Western blot	MCL-1 p-AKT / AKT / p-ERK / ERK p-AMPKα / AMPKα / p-ACC / ACC SHH / SMO / GLI1 / Bcl-2 / Foxm1		26918349
Growth inhibition assay	Cell proliferation Cell viability		28446712

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호	모집	조건	스폰서/협력자	시작일	단계
NCT05960864	Not yet recruiting	Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)\|Non-radiographic Axial Spondyloarthritis (Nr-axSpA)\|Axial Psoriatic Arthritis (axPsA)\|Acute Anterior Uveitis (AAU)\|Crohn Disease (CD)\|Ulcerative Colitis (UC)\|Reactive Arthritis (ReA)	Southwest Hospital China	September 2024	--
NCT05868525	Recruiting	Blunt Cerebrovascular Injury	Loma Linda University	July 2024	Phase 4
NCT06197009	Not yet recruiting	Axial Spondyloarthritis	Sinocelltech Ltd.	July 1 2024	Phase 2
NCT06378398	Not yet recruiting	Colorectal Neoplasia	University of Michigan Rogel Cancer Center\|National Cancer Institute (NCI)	May 2024	Early Phase 1

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Aspirin COX 억제제

화학 구조

분자량: 180.16